ACADIA Pharma initiates phase 3 CLARITY program with pimavanserin for MDD
ACADIA Pharmaceuticals announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in the upcoming months. These studies will evaluate the efficacy and safety of pimavanserin as adjunctive treatment in patients with major depressive disorder. April 25, 2019